Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 recruitment has begun following positive data from Cohort 1 Aethlon Medical (NASDAQ:AEMD) announced FY 2Q (quarter ended September 30, 2025) results ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Detailed price information for Hcw Biologics Inc (HCWB-Q) from The Globe and Mail including charting and trades.

A breast cancer vaccine, if proven safe and effective, could be a lifeline for Indian women who lack access to regular ...

Merck & Co has struck a $9.2 billion deal to acquire biotechnology company Cidara Therapeutics in a move that bolsters the US ...

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.